Recommendations for dose calculations of lung cancer treatment plans treated with stereotactic ablative body radiotherapy (SABR)

被引:2
|
作者
Devpura, S. [1 ]
Siddiqui, M. S. [1 ]
Chen, D. [1 ]
Liu, D. [1 ]
Li, H. [1 ]
Kumar, S. [1 ]
Gordon, J. [1 ]
Ajlouni, M. [1 ]
Movsas, B. [1 ]
Chetty, I. J. [1 ]
机构
[1] Henry Ford Hlth Syst, Detroit, MI 48202 USA
关键词
MONTE-CARLO; RADIATION-THERAPY; PHOTON BEAMS; ALGORITHM; VMC;
D O I
10.1088/1742-6596/489/1/012007
中图分类号
O59 [应用物理学];
学科分类号
摘要
The purpose of this study was to systematically evaluate dose distributions computed with 5 different dose algorithms for patients with lung cancers treated using stereotactic ablative body radiotherapy (SABR). Treatment plans for 133 lung cancer patients, initially computed with a 1D-pencil beam (equivalent-path-length, EPL-1D) algorithm, were recalculated with 4 other algorithms commissioned for treatment planning, including 3-D pencil-beam (EPL-3D), anisotropic analytical algorithm (AAA), collapsed cone convolution superposition (CCC), and Monte Carlo (MC). The plan prescription dose was 48 Gy in 4 fractions normalized to the 95% isodose line. Tumors were classified according to location: peripheral tumors surrounded by lung (lung-island, N=39), peripheral tumors attached to the rib-cage or chest wall (lung-wall, N=44), and centrally-located tumors (lung-central, N=50). Relative to the EPL-1D algorithm, PTV D95 and mean dose values computed with the other 4 algorithms were lowest for "lung-island" tumors with smallest field sizes (3-5 cm). On the other hand, the smallest differences were noted for lung-central tumors treated with largest field widths (7-10 cm). Amongst all locations, dose distribution differences were most strongly correlated with tumor size for lung-island tumors. For most cases, convolution/superposition and MC algorithms were in good agreement. Mean lung dose (MLD) values computed with the EPL-1D algorithm were highly correlated with that of the other algorithms (correlation coefficient =0.99). The MLD values were found to be similar to 10% lower for small lung-island tumors with the model-based (conv/superposition and MC) vs. the correction-based (pencil-beam) algorithms with the model-based algorithms predicting greater low dose spread within the lungs. This study suggests that pencil beam algorithms should be avoided for lung SABR planning. For the most challenging cases, small tumors surrounded entirely by lung tissue (lung-island type), a Monte-Carlo-based algorithm may be warranted.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Stereotactic ablative body radiotherapy (SABR) for early lung cancer: implementation and outcomes at University College London Hospital
    Osborn, K.
    Ahmed, M.
    Allington, L.
    Haji, N.
    Mendes, R.
    LUNG CANCER, 2014, 83 : S61 - S61
  • [22] Quality of Life and Symptoms in Patients Undergoing Stereotactic Ablative Body Radiotherapy (SABR) for Early Stage Lung Cancer
    Gray, C.
    Wingate, E.
    Ghafoor, Q.
    CLINICAL ONCOLOGY, 2018, 30 (06) : E56 - E56
  • [23] IAEA RCA 6065: IMPROVING ACCESS TO STEREOTACTIC ABLATIVE BODY RADIOTHERAPY (SABR) FOR LUNG CANCER PATIENTS IN ASIA
    Hegi-Johnson, Fiona
    Siva, Shankar
    Foote, Matthew
    Tan, Daniel
    Kim, Mi-Sook
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1130 - S1130
  • [24] Clinical outcomes of stereotactic ablative body radiotherapy (SABR) in medically inoperable early stage lung cancer patients
    Groves, Jonathan
    Yeo, Ryan
    Tsang, Yat
    Shah, Nihal
    Win, Thida
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [25] Outcomes in locally recurrent rectal cancer treated with reirradiation stereotactic ablative radiotherapy (SABR)
    Muirhead, R.
    Aitken, K.
    Holmes, J.
    Harrison, M.
    Harji, D.
    O'Cathail, S.
    Taylor, C.
    Wing, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1041 - S1042
  • [26] Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors
    Chaudhuri, Aadel A.
    Tang, Chad
    Binkley, Michael S.
    Jin, Michelle
    Wynne, Jacob F.
    von Eyben, Rie
    Hara, Wendy Y.
    Trakul, Nicholas
    Loo, Billy W., Jr.
    Diehn, Maximilian
    LUNG CANCER, 2015, 89 (01) : 50 - 56
  • [27] Identifying dosimetric predictors of toxicity in multiple lung tumors treated with stereotactic ablative radiotherapy (SABR)
    Tekatli, H.
    Tetar, S.
    Warner, A.
    Palma, D.
    Verbakel, W.
    Nguyen, T.
    Spoelstra, F.
    Gaede, S.
    Slotman, B.
    Senan, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S143 - S143
  • [28] Factors Affecting Use of Stereotactic Ablative Radiotherapy (SABR) in Patients with Inoperable Lung Cancer
    Syed, Mohshin
    Jayasekera, Geeshath
    Rushd, Farwah
    LUNG CANCER, 2025, 200
  • [29] EARLY DETECTION OF RECURRENCE IN PATIENTS TREATED WITH LUNG STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) USING RADIOMICS
    Kunkyab, Tenzin
    Mou, Benjamin
    Jirasek, Andrew
    Haston, Christina
    Andrews, Jeffrey
    Thomas, Steven
    Hyde, Derek
    RADIOTHERAPY AND ONCOLOGY, 2020, 150 : S31 - S31
  • [30] On the dose to a moving target in stereotactic ablative body radiotherapy to lung tumors
    Feygelman, V.
    Dilling, T. J.
    Moros, E. G.
    Zhang, G. G.
    MICRO-MINI & NANO-DOSIMETRY & INNOVATIVE TECHNOLOGIES IN RADIATION THERAPY (MMND&ITRO2016), 2017, 777